Alnylam PharmaceuticalsvsMerck & Company

ALNY and MRK stock compared: price, dividend, valuation and results, from SEC filings.

ALNY

Alnylam Pharmaceuticals, Inc.

$147.82

Value $19.6B

-1.06%
ALNY's page

MRK

Merck & Company, Inc.

$132.81

Value $328B

-3.61%
MRK's page

Alnylam Pharmaceuticals (ALNY) has a market value of $19.6B and Merck & Company (MRK) $328B. Over the last year, with dividends, ALNY moved -68.0% and MRK +41.8%. Dividend yield: ALNY none, MRK 2.56%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ALNY$19.6B

    MRK$328B

    MRK is 17 times ALNY

  • Revenue, 12 months

    ALNY$5.0B

    MRK$67.4B

    MRK is 13 times ALNY

  • Net income, 12 months

    ALNY$2.6B

    MRK$2.5B

    ALNY is 1.1 times MRK

  • Operating margin

    ALNY19.5%

    MRK–

  • ROIC

    ALNY31.8%

    MRK3.9%

    27.9 points apart

  • P/E

    ALNY–

    MRK133.9

  • Dividend yield

    ALNY0.0%

    MRK2.6%

    2.6 points apart

  • 5-year return

    ALNY-17.4%

    MRK+86.3%

    103.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ALNY-17.4%

MRK+86.3%

10020020222023202420252026
Returns by period
PeriodALNYWith dividendsMRKWith dividends
1 year since November 18, 2025-68.0%Price -68.0%+41.8%Price +37.7%
3 years since November 17, 2023-9.7%-3.4% a yearPrice -9.7%+43.1%+12.7% a yearPrice +30.5%
5 years since November 18, 2021-17.4%-3.8% a yearPrice -17.4%+86.3%+13.2% a yearPrice +59.9%
10 years since November 21, 2016+213.5%+12.1% a yearPrice +213.5%+203.1%+11.7% a yearPrice +123.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ALNYAlnylam PharmaceuticalsMRKMerck & Company

Valuation

ALNYMRK
Valuation
Price$147.82$132.81
Market value$19.6B$328B
Enterprise value (EV)–$372B
P/E–133.9
P/E, 5-year median–14.8
P/B5.47.3
EV/EBIT–78.2
Free cash flow yield4.1%4.5%

Results and growth

ALNYMRK
Results and growth
Revenue, 12 months$5.0B$67.4B
Net income, 12 months$2.6B$2.5B
Free cash flow, 12 months$806M$14.7B
Earnings per share, 12 months$19.98$0.98
Revenue growth, year on year65.2%1.3%
Revenue growth a year, past+49.8%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

ALNYMRK
Margins and returns on capital
Gross margin77.4%71.8%
Operating margin19.5%–
Net margin52.8%3.6%
ROIC31.8%3.9%
ROE178.9%5.2%

Balance sheet

ALNYMRK
Balance sheet
Cash$3.6B$9.7B
Total debt–$53.8B
Net debt / EBITDA–5.7
Interest cover3.3×2.4×

Dividends and buybacks

ALNYMRK
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.6%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ALNY or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Alnylam Pharmaceuticals or Merck & Company?

By market value, Merck & Company ($328B) is about 16.7 times Alnylam Pharmaceuticals ($19.6B), at today's prices.

How did ALNY and MRK stock do over the last 10 years?

Since November 21, 2016, ALNY's price moved +213.5% and MRK's +123.4%. With dividends: ALNY +213.5% (+12.1% a year), MRK +203.1% (+11.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, ALNY or MRK?

The dividend yield at today's price is none for Alnylam Pharmaceuticals and 2.56% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Alnylam Pharmaceuticals or Merck & Company?

Over the last twelve months, the net margin was 52.8% for Alnylam Pharmaceuticals and 3.6% for Merck & Company, and the operating margin 19.5% and –. Revenue was $5.0B and $67.4B.

Which is the better investment, Alnylam Pharmaceuticals or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.